The body's hidden fire: how a newly discovered form of cell death is changing how researchers think about ALS

Richard Moore
6 days ago
17 min read

If amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) in the UK, has touched your life, whether it's your diagnosis, someone you love, or patients you care for, you'll already know that one of the hardest things about this disease isn't what it takes. It's the silence where the explanation should be. The not-knowing why.

This piece is about a strand of biology that may help fill some of that silence. It won't give you a cure, nothing does that yet, but it will walk you through something scientists have been piecing together over the past decade: a mechanism specific enough, and consistent enough, that it's now one of the increasingly active areas in ALS research. It's called ferroptosis. Almost no one outside a neuroscience lab has heard of it. By the end, you'll understand why ferroptosis has become one of the most closely studied mechanisms in ALS research, what it does, and does not, mean in practice.

And if that's where this ends up helping you, that's enough.

The moment a scientist realises something completely new has been found

Science doesn't often announce itself with a fanfare. Usually it shows up as confusion, a cell doing something it has no business doing, dying in a way that doesn't fit any existing category. That's what happened in 2012, when a researcher named Scott Dixon and his colleagues at Columbia University were studying cancer cell death. They were using a compound called erastin, expecting to see the cell death they already knew, the clean, orderly self-destruction called apoptosis that biologists had spent decades mapping. What they saw was something else entirely (Dixon et al., 2012).

The cells were dying. But not like that. No classic signs of apoptosis. No classic signs of necrosis, the explosive, injury-type cell death. The dying looked different, and they eventually traced it back to a specific interaction between iron and the fats that make up cell membranes. They named what they'd found ferroptosis, from the Latin ferrum, iron.

Nobody in that lab could have predicted that the mechanism they'd just named would come to feature so prominently in research into Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS. But that's where a decade of science has landed (Ding et al., 2024; Kunz et al., 2025).

So why now? And why does it matter so much for ALS specifically?

What ALS actually does - and why understanding the biology matters

To understand why ferroptosis matters, you need to understand what ALS is actually doing at the cellular level, because that's where this gets specific, and specific is where medicine becomes useful.

ALS progressively destroys motor neurones, the nerve cells in the brain and spinal cord whose entire job is to carry electrical signals to muscles, telling them to move. As those neurones deteriorate, the muscles they're connected to go quiet. The result is the gradual loss of voluntary movement that most people recognise as the hallmark of the disease.

But what's been driving researchers for decades isn't the clinical picture, it's what's happening at the molecular level long before any of that begins. Motor neurones are remarkable cells. Some stretch over a metre from the spinal cord all the way to the muscles of the feet. They're among the most metabolically demanding cells in the body, burning through vast amounts of energy and relying on powerful antioxidant systems to keep themselves intact across a lifetime. They're built to last. So what starts stripping that protection away?

For roughly 90 % of people with ALS, there's no inherited genetic mutation that explains it (Brown & Al-Chalabi, 2017). No family history. No obvious single cause. That absence, the not-knowing, is often what people living with the disease find hardest to carry. Science doesn't have a complete answer yet. But ferroptosis is, increasingly, part of one.

What Is ferroptosis? An honest, plain-english explanation

Ferroptosis is a specific type of cell death, and that's a more important distinction than it first appears. For most of the 20th century, scientists thought cells died in one of two main ways: apoptosis (an organised, almost quiet self-destruction the cell undergoes when it's too damaged to continue) or necrosis (the chaotic death caused by injury, infection or toxins). Ferroptosis is neither. It has its own triggers, its own molecular machinery, and its own signature in tissue, distinct enough that it took until 2012 for anyone to even recognise it as a separate thing (Ding et al., 2024).

Here's how to picture it. The outer wall of a cell isn't solid, it's more like a fabric, woven from fats. Specifically, a class of fats called polyunsaturated fatty acids, or PUFAs. These keep the cell wall flexible and functional, but they have a serious vulnerability: they're easily damaged by a process called oxidation. When a reactive molecule, a free radical, collides with one of these fatty molecules, it steals an electron. That destabilises the fat molecule, which then steals from its neighbour. Which steals from its neighbour. It's a chain reaction, a spreading wave of damage that, if nothing stops it, eventually causes the cell wall to rupture. Iron is the accelerant. When free iron is present, iron that isn't safely packaged and stored the way the body intends, it generates an especially destructive type of free radical. These hit the fatty cell wall, the chain reaction catches more easily, spreads faster. Iron doesn't start the fire exactly. But it makes it immeasurably worse.

Under normal conditions, the body has a fire suppression system for exactly this. The central component is an enzyme called glutathione peroxidase 4 (GPX4) - think of it as a molecular fire extinguisher. Its job is to intercept the damaged fat molecules before they can attack their neighbours, converting them from toxic to harmless. GPX4 runs on glutathione, a protective molecule the body builds from amino acids, including one called cysteine. And to make cysteine, the cell depends on a tiny gateway protein embedded in its own wall, a molecular door that imports the raw ingredient from outside. When everything works, that door stays open, the ingredients arrive, glutathione gets made, the fire extinguisher stays loaded, and the cell survives.

Block the door, and everything unravels. The raw materials run out. Glutathione falls. The fire extinguisher empties. The chain reaction spreads unchecked. Iron pours fuel on it. The cell wall collapses. That's ferroptosis (Kunz et al., 2025; Ding et al., 2024).

The finding that stopped researchers in their tracks: 80%

In 2022, a research group published a paper in Cell Death & Differentiation that, quietly, without fanfare, shifted the direction of ALS research. They examined post-mortem spinal cord tissue from both sporadic and familial ALS patients and looked at levels of GPX4, the fire-extinguisher enzyme (Wang et al., 2022).

What they found was stark. In the spinal cords of familial ALS patients, GPX4 protein levels were depleted by approximately 55% compared to healthy controls. In sporadic ALS, the most common form, the one with no clear genetic cause, the depletion was even more severe. GPX4 was reduced by approximately 80%. Nearly gone (Wang et al., 2022). Read that again. In the very tissue being destroyed by ALS, the body's primary molecular defence against ferroptosis is almost completely absent. And this was not found in one genetic subtype. It was found across multiple genetic subtypes of ALS, including those caused by mutations in SOD1, TDP-43, and C9orf72, three genes discussed in more detail below, and in human tissue from sporadic patients who had never been told they had a genetic form of the disease.

This is not a small signal. An 80% reduction in one of the cell's key anti-ferroptosis enzymes, in the tissue most affected by ALS, is a striking finding. It does not prove ferroptosis is the cause of ALS, but it strongly suggests this form of cell death deserves serious research attention.

GPX4 depletion also showed up early. It was present in symptomatic ALS mice before motor neurone death became obvious, suggesting this is not simply a consequence of dying cells losing their proteins, but something happening in the lead-up to cell death itself (Wang et al., 2022). This is important because it suggests ferroptosis may not only be involved in ALS once damage is established, but could potentially be detected earlier in the disease process.

Importantly, this does not mean ALS is a ferroptosis disease in isolation. ALS remains understood as a multi-system disorder involving overlapping genetic, metabolic, inflammatory, mitochondrial, and environmental pressures. Ferroptosis is one significant piece of an incomplete picture.

Why motor neurones are the weakest link in this story

Once you understand ferroptosis, why motor neurones are so vulnerable stops looking like bad luck.

Motor neurones are long, metabolically demanding cells that produce large amounts of free radicals, the same reactive molecules described in the ferroptosis section, simply as a by-product of their energy generation. More metabolic activity means more oxidative stress. More oxidative stress means greater pressure on the antioxidant systems that guard against ferroptosis. A cell that burns bright burns through its protective reserves faster.

The motor neurone environment is also high in glutamate, the brain's primary excitatory neurotransmitter. In ALS, glutamate clearance is impaired, meaning it accumulates around motor neurones at elevated concentrations. This creates a specific problem for ferroptosis defence. Recall that the molecular gateway importing the raw materials for glutathione works by exporting glutamate. When glutamate is already backed up outside the cell, the gateway struggles to push more out, which means it cannot efficiently pull raw materials in. The result is a cysteine shortage, a glutathione deficit, and a GPX4 fire extinguisher running dangerously low (Kobayashi et al., 2025).

What makes this so significant is that ferroptosis may help connect two problems researchers have long studied in ALS: toxic glutamate accumulation and oxidative stress. They are not completely separate problems, they can feed into the same cascade, with both accelerating ferroptosis.

In 2025, a research team used induced pluripotent stem cell (iPSC)-derived motor neurones, one of the closest experimental models science currently has for studying living human motor neurones, and showed that oxidative stress-induced neuronal damage in these cells was accompanied by the kind of membrane fat damage described earlier and was suppressible by ferroptosis inhibitors and an iron chelator. The same team found that edaravone, one of the two approved treatments for ALS, was neuroprotective in this model - while riluzole, the other approved drug, was not (Kobayashi et al., 2025). That distinction is significant: it suggests edaravone's mechanism of action overlaps meaningfully with ferroptosis inhibition.

The genetics: why some people and not others?

If motor neurones are this vulnerable, you might reasonably wonder why ALS isn't far more common. Why does the system hold for most people across an entire lifetime, and then fail in others?

We don't fully know. But the genetics of ALS offer some revealing clues about where those failure points are.

The most studied familial ALS mutation involves the gene SOD1, which encodes an antioxidant enzyme that neutralises one of the primary reactive molecules produced during normal cellular metabolism. When SOD1 is mutated, antioxidant defences are compromised from the start, and oxidative stress builds more quickly. In multiple animal models carrying SOD1 mutations, deliberately removing GPX4, the anti-ferroptosis enzyme, from motor neurones triggers rapid neurodegeneration. Restoring it, or overexpressing it, delays disease onset and extends lifespan (Wang et al., 2022).

Then there is TDP-43, whose mishandling appears in over 97% of all ALS cases, familial and sporadic alike. TDP-43 is a protein that normally lives in the cell nucleus, managing RNA. Under oxidative stress, it relocates to the cytoplasm, aggregates into toxic clumps, and loses its normal function. The connection to ferroptosis is circular and damaging: oxidative stress causes TDP-43 to malfunction, and malfunctioning TDP-43 makes cells more vulnerable to further oxidative stress (Brown & Al-Chalabi, 2017).

In 2024, a study specifically examining FUS-ALS, a subtype caused by mutations in a gene called FUS (fused in sarcoma), found that these cells showed heightened vulnerability to ferroptosis compared to controls, alongside reduced expression of the very gateway protein responsible for importing cystine, a precursor to cysteine, for glutathione synthesis (Increased Vulnerability to Ferroptosis in FUS-ALS, 2024). A cell with less cystine coming in makes less glutathione. Less glutathione means less GPX4 activity. Less GPX4 activity means antioxidant protection is already compromised before anything else goes wrong.

Beyond specific mutations, age is the single greatest risk factor for sporadic ALS, and age is accompanied by a well-documented, progressive decline in GPX4 levels, glutathione production, and the efficiency of iron handling throughout the brain. A cell that managed these systems adequately at 40 may no longer be able to at 65. Environmental exposures, heavy metals, certain pesticides, chronic inflammatory stressors, may further erode the margins. The picture is not of a single trigger but of a threshold: a lifetime of accumulated pressure on the ferroptosis defence system, until the point where it cannot hold.

What the science is doing about it - and how close we actually are

This is also where intellectual honesty matters most, because the science is genuinely exciting, and excitement can distort things if you're not careful.

Here's what makes ferroptosis different from so many dead ends in ALS research: it's regulated. Not random damage. Not chaos. It has defined molecular mechanisms, identifiable failure points, measurable signatures. And regulated processes can, in principle, be interrupted. The question is how, how safely, and how soon.

Researchers are now exploring several ways to interrupt this biology. Reducing free iron through chelating agents, including deferiprone, already approved in other conditions, has shown protective effects in ALS models. Compounds that stabilise GPX4 or activate Nrf2 (Nuclear factor erythroid 2-related factor 2), the master regulator controlling GPX4, glutathione synthesis, and iron management simultaneously, have both demonstrated neuroprotective effects in ALS-relevant experimental settings (Zhou et al., 2024; NRF2 activation suppresses motor neuron ferroptosis, 2023). CuATSM, a copper-containing compound in active clinical trials for ALS, also has anti-ferroptosis properties (Zhou et al., 2024). And in 2025, the most ambitious patient-derived drug screen yet conducted in ALS - testing across motor neurones from 100 sporadic patients, identified a combination of existing drugs as a potential therapeutic strategy (Large-scale drug screening in iPSC-derived motor neurones, 2025).

Some of these approaches remain early-stage; others are entering more formal investigation. What distinguishes this moment from earlier periods in ALS research is not any single compound but the mechanistic clarity: researchers have another specific molecular target and are working backwards from a defined failure point.

We are not yet at a clinical trial specifically targeting ferroptosis in ALS patients. But the question of how to interrupt this process is no longer theoretical.

The defence system is built in. Does it have what it needs?

While the pharmaceutical pipeline develops, there's a biochemical reality worth understanding right now. Every component of the ferroptosis defence system, the fire extinguisher enzyme, the glutathione that fuels it, the master switch that controls production, the backup membrane defender, depends on raw materials that come from food, or what the body can absorb from it. When those materials run short, the system runs at reduced capacity.

Nutrition doesn't treat ALS, nothing in what follows should be read as a claim that it does. What follows is mechanistic reasoning: the science of which raw materials the ferroptosis defence system requires and whether those might be in short supply. It is grounded in real biochemistry, but clinical trials in ALS patients have not established that nutritional interventions alter disease course.

The defence against ferroptosis has three distinct layers. There is the fire extinguisher itself and the raw materials needed to keep it loaded. There is the protective fabric woven into the cell membrane that stops the fire spreading in the first place. And there is the master control switch that, when activated, turns up the production of everything else. Each layer has nutritional dependencies.

Start with GPX4, the enzyme depleted by up to 80% in the spinal cord tissue of sporadic ALS patients. It is a selenoprotein, meaning selenium is physically built into its active site (Wang et al., 2022). Without adequate selenium, GPX4 cannot be correctly synthesised; research has shown that supplementation enhances both its gene transcription and protein levels (Exploring the Neuroprotective Role of Selenium, 2024).

GPX4 also needs glutathione as its operating fuel, and glutathione is built from cysteine, an amino acid the cell normally imports through the molecular gateway described earlier. When that gateway is under stress, as it may be in the glutamate-saturated environment of an ALS motor neurone, cysteine becomes scarce. That's where N-acetylcysteine (NAC) becomes relevant: a direct cysteine precursor that gives the cell an alternative route in, bypassing the jammed gateway. Together, selenium and NAC map onto two core biochemical prerequisites for GPX4 function, one supporting the enzyme's structure, the other supporting glutathione availability. The rationale is mechanistic; ALS-specific clinical trials for these compounds do not yet exist.

The second layer is the membrane itself. Vitamin E, specifically the tocopherol family, helps intercept lipid radicals before they can steal electrons from neighbouring fats and propagate membrane damage (Mechanisms of Vitamins Inhibiting Ferroptosis, 2024). Sunflower seeds, almonds, hazelnuts, olive oil, and avocado are all meaningful food sources. Some practitioners prefer mixed tocopherol formulations over isolated alpha-tocopherol, although ALS-specific evidence is lacking. Alongside vitamin E, Coenzyme Q10 (CoQ10, or ubiquinol in its active form) fuels the secondary ferroptosis suppression system: Ferroptosis Suppressor Protein 1 (FSP1) uses CoQ10 to quench lipid radicals at the membrane when GPX4 is under pressure. Motor neurones also depend on CoQ10 for mitochondrial energy production, giving it two independent mechanistic rationales in this context (Frontiers, 2025).

The third layer, arguably the most upstream, is the master control switch: Nrf2, the protein that, when activated, simultaneously increases production of GPX4, glutathione-synthesising enzymes, and iron-management proteins. Several food compounds are among the most potent known natural Nrf2 activators. Sulforaphane, found in broccoli sprouts at concentrations 20 to 100 times higher than in mature broccoli, activates Nrf2 with a consistency that has drawn serious pharmaceutical interest. Quercetin, abundant in red onions, capers, apples, and dark berries, activates Nrf2, but also chelates free iron and has been shown to inhibit ferroptosis through a separate iron-coordination mechanism that operates independently of Nrf2 (Quercetin and resveratrol inhibit ferroptosis, 2022), three mechanistically distinct effects within the same pathway. Curcumin shares quercetin's iron-chelating and Nrf2-activating properties, though its poor absorption from standard preparations means specialist formulations, such as phospholipid complexes or preparations enhanced with piperine, a compound from black pepper that improves absorption, are required when the intent is therapeutic rather than culinary (Ali et al., 2025).

One nuance worth noting: DHA, the primary omega-3 in neuronal membranes, is also the membrane fatty acid most vulnerable to lipid peroxidation. That's not a reason to avoid omega-3s; their structural and anti-inflammatory roles in neural tissue are well established. It is a reason to ensure that when omega-3 intake is high, membrane-protective nutrients such as vitamin E and selenium are adequately supplied alongside them.

The point here is not that these nutrients treat ALS. It is that the ferroptosis defence system is nutritionally dependent, and in practice, that means clinicians may reasonably consider whether someone has adequate protein intake, selenium status, iron balance, antioxidant capacity, and dietary diversity before considering targeted nutritional support.

Four principles that actually matter

Knowing the science and knowing what to do with it are different things. Here are four principles worth holding onto.

Test before you supplement. Some of the biochemical pressures relevant to ferroptosis can be assessed indirectly through blood testing, including iron status (ferritin, transferrin saturation, serum iron), selenium levels, glutathione, and oxidative stress markers, although these do not tell you whether ferroptosis is active in motor neurones specifically. What they may help show is whether some of the nutrients and biochemical systems linked to antioxidant defence and iron handling are under strain, which can be clinically useful when interpreted in context. Iron in particular requires testing before any intervention, because excess and deficiency require opposite responses, and treating one like the other causes harm. Without baseline data, decisions are much more likely to become guesswork.

Address the system, not just one part of it. Selenium enables GPX4. NAC restores the cysteine needed to make glutathione. Vitamin E guards the membrane. CoQ10 fuels the backup. Sulforaphane and quercetin activate the master switch that produces all of the above. These nutrients are not interchangeable, they address different failure points in the same defence network. Isolated supplementation without a full-system view is not a strategy, it's guesswork.

Do not underestimate movement. Regular, moderate physical exercise activates the Nrf2 pathway, measurably increasing GPX4 levels and glutathione production in neuronal tissue (Antioxidant-rich foods and exercise, 2025). For people living with ALS where mobility permits, and for anyone concerned about neurological resilience more broadly, exercise is one of the more accessible ways to support antioxidant signalling where it is safe, realistic, and clinically appropriate.

Work with someone who understands your specific clinical picture. Someone on riluzole and edaravone has drug-nutrient interactions to navigate. Someone with high ferritin needs a completely different iron strategy than someone depleted. Someone managing ALS-related fatigue needs supplement timing and dosing calibrated to their functional capacity. What this article gives you is a framework. What a practitioner gives you is a plan.

A word of honesty - because you deserve it

You've worked through some genuinely demanding science in this piece. That's a choice, and it says something about the kind of answer you're actually looking for.

So here it is plainly: ferroptosis is not yet a clinical target with an approved therapy in ALS. The mechanistic case is compelling, the research trajectory is steep, and the pharmaceutical interest is real, but we're not there yet. The nutritional strategies in this piece are grounded in genuine biochemistry and rationally defensible within the framework we've described. They are not treatments for the disease itself.

What they are is a rational, evidence-informed way to support some of the molecular systems increasingly implicated in motor neurone vulnerability (Wang et al., 2022; Ding et al., 2024). That's worth something. In a disease where the most honest answer has so often been we don't know why, having a mechanism specific enough to work with represents real progress. Not enough. But a different kind of not-enough than there was a decade ago.

Knowing the name of the fire isn't the same as putting it out. But it's always how you start.

What this does not mean

This does not mean ALS is caused by iron alone. It does not mean everyone with ALS should take iron chelators, selenium, NAC, or antioxidant supplements. It does not mean blood tests can confirm that ferroptosis is active inside motor neurones. What it does mean is that iron handling, lipid oxidation, glutathione, GPX4, and antioxidant resilience are becoming important areas of research in ALS, offering a mechanistic framework that may help guide future clinical investigation and cautious, evidence-informed nutritional support.

This is where you begin

You came to this article searching for something. If you found even part of what you were looking for, a clearer picture of what might be happening, a framework you can take to your clinical team, a sense that the science is moving, then this piece has done its job.

At You Nutrition Clinic, we work with people navigating exactly this territory. Individuals living with ALS and their families who want to understand their own biochemistry. Clinicians and functional medicine practitioners building nutritional strategies grounded in the latest research. People who want to explore the nutritional and biochemical systems linked to oxidative stress, iron balance, and antioxidant resilience, and what evidence-informed support looks like for their specific picture.

Where appropriate, we can consider testing such as iron panels, selenium status, glutathione, and oxidative stress markers, always interpreted alongside symptoms, diet, medication use, and clinical context. We offer personalised nutritional support built around your specific results, not generic advice. We don't offer cures. We offer precision, rigour, and the kind of care that takes the science as seriously as you do.

If you would like support interpreting your own nutritional and biochemical picture in the context of ALS, you can book a consultation with You Nutrition Clinic by contacting admin@younutritionclinic.com.

🧩 Connect with us

For research updates, practical tips, and ongoing inspiration, follow us on Instagram:

👉 @nutritionandthebrain

👉 @younutritionkids

Stay curious. Stay hopeful. Support your brain. 🧠

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult with a qualified, registered medical doctor (MD) for diagnosis and treatment decisions.

References

Ali, S., Farhan, M., & Hasan, M. (2025). Emerging links between ferroptosis and neurodegeneration: Implications for disease mechanisms and nutraceutical interventions. Food Science & Nutrition. https://doi.org/10.1002/fsn3.70385

Antioxidant-rich functional foods and exercise: Unlocking metabolic health through Nrf2 and related pathways. (2025). PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11817741/

Brown, R. H., & Al-Chalabi, A. (2017). Amyotrophic lateral sclerosis. New England Journal of Medicine, 377(2), 162–172. https://doi.org/10.1056/NEJMra1603471

Ding, Y., Zhang, X., & Li, Y. (2024). The role of ferroptosis in neurodegenerative diseases. Frontiers in Cellular Neuroscience, 18, 1475934. https://doi.org/10.3389/fncel.2024.1475934

Ding, Y., & Wu, J. (2025). Crosstalk between microbiota and ferroptosis in diseases: From mechanism to therapy. Comprehensive Physiology. https://doi.org/10.1002/cph4.70042

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., Morrison, B., 3rd, & Stockwell, B. R. (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 149(5), 1060–1072. https://doi.org/10.1016/j.cell.2012.03.042

Exploring the neuroprotective role of selenium. (2024). Experimental Results, 5, e42. https://doi.org/10.1002/EXP.20240415

Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases. (2024). PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10861688/

Frontiers. (2025). Q-Der: A next-generation CoQ10 analogue supercharging neuroprotection by combating oxidative stress and enhancing mitochondrial function. Frontiers in Molecular Biosciences, 12, 1525103. https://doi.org/10.3389/fmolb.2025.1525103

Increased vulnerability to ferroptosis in FUS-ALS. (2024). PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11048265/

Kobayashi, M., Tanaka, H., & Watanabe, T. (2025). Neuronal damage induced by gradual oxidative stress in iPSC-derived neurons: Implications for ferroptosis involvement and ALS drug evaluation. Journal of Neurochemistry. https://doi.org/10.1111/jnc.70246

Kunz, J., Abdukarimov, N., & Kokabi, K. (2025). Ferroptosis and iron homeostasis: Molecular mechanisms and neurodegenerative disease implications. Antioxidants, 14(5), 527. https://doi.org/10.3390/antiox14050527

Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy. (2025). Nature Neuroscience. https://doi.org/10.1038/s41593-025-02118-7

Mechanisms of vitamins inhibiting ferroptosis. (2024). PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673384/

Natural flavonoids from herbs and nutraceuticals as ferroptosis inhibitors in central nervous system diseases: Current preclinical evidence and future perspectives. (2025). Frontiers in Pharmacology, 16, 1570069. https://doi.org/10.3389/fphar.2025.1570069

NRF2 activation suppresses motor neuron ferroptosis induced by the SOD1G93A mutation and exerts neuroprotection in amyotrophic lateral sclerosis. (2023). Neurobiology of Disease, 185, 106240. https://doi.org/10.1016/j.nbd.2023.106240

Quercetin and resveratrol inhibit ferroptosis independently of Nrf2–ARE activation in mouse hippocampal HT22 cells. (2022). Food and Chemical Toxicology, 161, 112804. https://doi.org/10.1016/j.fct.2022.112804

Selenium in amyotrophic lateral sclerosis: Mendelian randomization study. (2021). PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527026/

Vasta, R., Calvo, A., Mazzini, L., & Chio, A. (2026). Amyotrophic lateral sclerosis prevalence projection in 2040: A less rare disease. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70226

Wang, T., Tomas, D., Perera, N. D., Cuic, B., Luikinga, S., Viden, A., Barton, S. K., McLean, C. A., Samson, A. L., Southon, A., Bush, A. I., Murphy, J. M., & Turner, B. J. (2022). Ferroptosis mediates selective motor neuron death in amyotrophic lateral sclerosis. Cell Death & Differentiation, 29, 1187–1198. https://doi.org/10.1038/s41418-021-00910-z

Zhou, Y., Liang, X., & Li, H. (2024). Ferroptosis: Mechanisms and therapeutic targets. MedComm, 5(10), e70010. https://doi.org/10.1002/mco2.70010